Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker
Articolo
Data di Pubblicazione:
2014
Citazione:
Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker / Furino, C; Boscia, Francesco; Recchimurzo, F.; Sborgia, N; Alessio, C.. - In: RETINA. - ISSN 0275-004X. - 34:8(2014), pp. 1612-1616. [10.1097/IAE.0000000000000105]
Abstract:
Abstract
PURPOSE::
To study the efficacy of a single 0.7 mg dexamethasone intravitreal implant in vitrectomized eyes with refractory macular edema secondary to combined cataract extraction and macular pucker removal.
METHODS::
In 8 eyes of 8 consecutive patients with refractory macular edema secondary to combined cataract extraction and 25-gauge vitrectomy with internal limiting membrane peeling for macular pucker removal, the injection of the 0.7 mg dexamethasone implant was performed. Best-corrected visual acuity, central retinal thickness measured by spectral domain optical coherence tomography, and intraocular pressure were evaluated at baseline, 1 month, and 6 months.
RESULTS::
After a mean follow-up of 6.75 ± 0.71 months, best-corrected visual acuity was significantly increased (P < 0.0001) from 20/50 to 20/23 (P < 0.0001), mean central retinal thickness decreased significantly from 439 ± 45 μm to 296 ± 49 μm (P < 0.0001), and intraocular pressure changed significantly (P = 0.02) from 14.63 ± 1.19 to 16 ± 0.93. In no case postoperative hypotony or other complication was observed.
CONCLUSION::
A single injection of the 0.7 mg dexamethasone intravitreal implant resulted effective in the treatment of refractory macular edema secondary to combined cataract extraction and vitrectomy for macular pucker removal allowing a stable visual acuity recovery.
PURPOSE::
To study the efficacy of a single 0.7 mg dexamethasone intravitreal implant in vitrectomized eyes with refractory macular edema secondary to combined cataract extraction and macular pucker removal.
METHODS::
In 8 eyes of 8 consecutive patients with refractory macular edema secondary to combined cataract extraction and 25-gauge vitrectomy with internal limiting membrane peeling for macular pucker removal, the injection of the 0.7 mg dexamethasone implant was performed. Best-corrected visual acuity, central retinal thickness measured by spectral domain optical coherence tomography, and intraocular pressure were evaluated at baseline, 1 month, and 6 months.
RESULTS::
After a mean follow-up of 6.75 ± 0.71 months, best-corrected visual acuity was significantly increased (P < 0.0001) from 20/50 to 20/23 (P < 0.0001), mean central retinal thickness decreased significantly from 439 ± 45 μm to 296 ± 49 μm (P < 0.0001), and intraocular pressure changed significantly (P = 0.02) from 14.63 ± 1.19 to 16 ± 0.93. In no case postoperative hypotony or other complication was observed.
CONCLUSION::
A single injection of the 0.7 mg dexamethasone intravitreal implant resulted effective in the treatment of refractory macular edema secondary to combined cataract extraction and vitrectomy for macular pucker removal allowing a stable visual acuity recovery.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
dexamethasone; dexamethasone; drug implant; glucocorticoid, aged; article; cataract extraction; central retinal thickness; clinical article; drug efficacy; epiretinal membrane; follow up; human; hypotony maculopathy; intraocular pressure; postoperative complication; postoperative period; retina detachment; retina hemorrhage; retina macula edema; retina tear; spectral domain optical coherence tomography; visual acuity; vitrectomy; drug effects; drug implant; macular edema; optical coherence tomography; pathology; physiology; retina; Retinal Diseases; retrospective study; vitrectomy; vitreous body, Aged; Cataract Extraction; Dexamethasone; Drug Implants; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Retina; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Vitreous Body; Dexamethasone implant; Intravitreal injection; Macular edema; Ozurdex
Elenco autori:
Furino, C; Boscia, Francesco; Recchimurzo, F.; Sborgia, N; Alessio, C.
Link alla scheda completa:
Pubblicato in: